Search Within

Hira Abbas Rizvi

Formats
  1. Journal Article (65)
  2. Meeting Abstract (58)
Groups
  1. Department of Medicine (123)
  2. Solid Tumor Oncology Division (123)
  3. Thoracic Oncology (121)
  4. GSK Faculty (67)
  5. Weinberg Fellows (63)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (59)

More Groups

People
  1. Matthew Hellmann (97)
  2. Gregory Riely (42)
  3. Andrew Plodkowski (41)
  4. Charles Rudin (37)
  5. Mark Kris (34)
  6. Kathryn Arbour (32)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (8)
  4. 2022 (17)
  5. 2021 (23)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Journal of Thoracic Oncology (16)
  3. Annals of Oncology (12)
  4. Clinical Cancer Research (12)
  5. Cancer Research (10)
  6. Cancer Cell (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (37)
  2. American Association for Cancer Research (28)
  3. Elsevier Inc. (20)
  4. Oxford University Press (13)
  5. Cell Press (7)
  6. American Medical Association (4)

More Publishers

Results (123)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC
    Journal Article

    Santini, F. C.; Rizvi, H.; Plodkowski, A. J.; Ni, A.; Lacouture, M. E.; Gambarin-Gelwan, M.; Wilkins, O.; Panora, E.; Halpenny, D. F.; Long, N. M.; more...
    Cancer Immunology Research (2018)

    Fulltext@MSK | Save
  • Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
    Journal Article

    Derosa, L.; Hellmann, M. D.; Spaziano, M.; Halpenny, D.; Fidelle, M.; Rizvi, H.; Long, N.; Plodkowski, A. J.; Arbour, K. C.; Chaft, J. E.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders
    Journal Article

    Leonardi, G. C.; Gainor, J. F.; Altan, M.; Kravets, S.; Dahlberg, S. E.; Gedmintas, L.; Azimi, R.; Rizvi, H.; Riess, J. W.; Hellmann, M. D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
    Journal Article

    Hellmann, M. D.; Nathanson, T.; Rizvi, H.; Creelan, B. C.; Sanchez-Vega, F.; Ahuja, A.; Ni, A.; Novik, J. B.; Mangarin, L. M. B.; Abu-Akeel, M.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors
    Journal Article

    Martin, M.; Sabari, J. K.; Turashvili, G.; Halpenny, D. F.; Rizvi, H.; Shapnik, N.; Makker, V.
    Gynecologic Oncology Reports (2018)

    Fulltext@MSK | Save
  • Histologic features predictive of response to PD-1 blockade in patients with non small cell lung carcinoma (NSCLC)
    Meeting Abstract

    Alex, D.; Travis, W.; Rekhtman, N.; Buonocore, D.; Ni, A.; Rizvi, H.; Hellmann, M.; Sauter, J. L.
    Modern Pathology (2018)

    Fulltext@MSK | Save
  • Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing
    Journal Article

    Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J. L.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
    Journal Article

    Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C. P. M.; Alou, M. T.; Daillè€re, R.; Fluckiger, A.; Messaoudene, M.; Rauber, C.; Roberti, M. P.; more...
    Science (2018)

    Fulltext@MSK | Save
  • Use of PD-1 pathway inhibitors among patients with non-small cell lung cancer (NSCLC) and preexisting autoimmune disorders
    Meeting Abstract

    Leonardi, G. C.; Gainor, J. F.; Azimi, R. S.; Riess, J.; Rizvi, H.; Hellmann, M. D.; Awad, M. M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Lesion response and intracranial control of brain metastases from non-small cell lung cancer after stereotactic radiosurgery or hypofractionated radiation therapy combined with checkpoint inhibitors
    Meeting Abstract

    Imber, B. S.; Hellmann, M. D.; Kris, M. G.; Santomasso, B. D.; Callahan, M. K.; Osorio, J.; Rizvi, H.; Chan, T. A.; Yang, T. J.; Yamada, Y.; more...
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save